Drug Profile
DCB AD1
Alternative Names: DCB-AD1Latest Information Update: 19 Mar 2019
Price :
$50
*
At a glance
- Originator Development Center for Biotechnology
- Class Antidementias; Herbal medicines; Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 19 Mar 2019 Discontinued - Phase-II for Alzheimer's disease (In the elderly, In adults) in Taiwan (unspecified route)